ThirdLaw Molecular
ThirdLaw Molecular LLC (branded online as Ladder Bio) is a drug-discovery and diagnostics company founded in 2020 to develop a novel class of chemically synthesized, structured oligomeric macromolecules for targeted therapeutics and diagnostic reagents. The organization designs and synthesizes large combinatorial libraries (including DNA-encoded libraries), applies computational molecular design and high-throughput screening to identify protein binders, and pursues research collaborations and scale-up manufacturing for candidate discovery. The company maintains policies and processes for PHS-funded research compliance.
Industries
Nr. of Employees
small (1-50)
ThirdLaw Molecular
Products
4.5-billion-member DNA-encoded library of structured synthetic macromolecules
A large DNA-encoded combinatorial library composed of chemically synthesized, structured fused-ring oligomer macromolecules designed for screening against protein targets.
Spiroligomer™ molecules
Spiroligomer™ molecules are a groundbreaking new therapeutic modality combining advantages of small molecules and biologics. They are larger than small molecules but ~1/100th the size of biologics, enabling cell permeability and access to intra- and extra-cellular targets, with potential oral bioavailability and protease resistance due to lack of peptide bonds. They are synthetic, non-immunogenic, conformationally rigid, highly stable, and computationally designed for selective binding to target proteins.
4.5-billion-member DNA-encoded library of structured synthetic macromolecules
A large DNA-encoded combinatorial library composed of chemically synthesized, structured fused-ring oligomer macromolecules designed for screening against protein targets.
Spiroligomer™ molecules
Spiroligomer™ molecules are a groundbreaking new therapeutic modality combining advantages of small molecules and biologics. They are larger than small molecules but ~1/100th the size of biologics, enabling cell permeability and access to intra- and extra-cellular targets, with potential oral bioavailability and protease resistance due to lack of peptide bonds. They are synthetic, non-immunogenic, conformationally rigid, highly stable, and computationally designed for selective binding to target proteins.
Services
Research collaborations with pharmaceutical and biotech organizations to discover and optimize selective synthetic macromolecule binders for target proteins.
DEL screening workflows and hit validation services to identify protein-binding candidates from multi-billion-member libraries.
Development of synthetic binding reagents and multiplex assay formats intended for point-of-care and at-home diagnostic applications.
Research collaborations with pharmaceutical and biotech organizations to discover and optimize selective synthetic macromolecule binders for target proteins.
DEL screening workflows and hit validation services to identify protein-binding candidates from multi-billion-member libraries.
Development of synthetic binding reagents and multiplex assay formats intended for point-of-care and at-home diagnostic applications.
Expertise Areas
- Targeted drug discovery using synthetic macromolecules
- DNA-encoded library (DEL) construction and screening
- Combinatorial library synthesis and scale-up
- Diagnostic reagent and multiplex assay development
Key Technologies
- Structured fused-ring synthetic oligomer macromolecules
- DNA-encoded libraries (DEL)
- High-throughput screening (HTS)
- Computational molecular design
News & Updates
Company scientist presented research on screening a 4.5 billion-member DNA-encoded library to identify protein binders; presentation selected for the Innovation AveNEW program at SLAS Europe 2025.
Announcement of the company’s platform for targeted drug discovery featuring a multi-billion-member DNA-encoded library of structured synthetic macromolecules.
Announcement of a senior medicinal chemist joining as scientific advisor to support drug discovery and development efforts.
External media article profiling the company’s scientific approach and technology.
Company presentation selected for the Innovation AveNEW program, recognizing disruptive scientific innovation and sponsoring conference participation.
Company scientist presented research on screening a 4.5 billion-member DNA-encoded library to identify protein binders; presentation selected for the Innovation AveNEW program at SLAS Europe 2025.
Announcement of the company’s platform for targeted drug discovery featuring a multi-billion-member DNA-encoded library of structured synthetic macromolecules.
Announcement of a senior medicinal chemist joining as scientific advisor to support drug discovery and development efforts.
External media article profiling the company’s scientific approach and technology.
Company presentation selected for the Innovation AveNEW program, recognizing disruptive scientific innovation and sponsoring conference participation.